



Thank you for your interest in ICLIO Grand Rounds, a personalized learning initiative conducted by the Institute for Clinical Immuno-Oncology (ICLIO), an institute of the Association of Community Cancer Centers (ACCC).

ICLIO Grand Rounds will provide evidence-based information on the latest developments in the use of cancer immunotherapy and effective management of associated immune-related adverse events. Led by an ICLIO expert, the Grand Rounds will be held on site at your institution. The ICLIO Grand Rounds program aims to assist clinicians in their everyday decision-making regarding difficult, real-world cases when treating patients with immuno-oncology agents.

To be considered for this opportunity, your institution must meet all of the following criteria:

- Be a current ACCC Cancer Program Member.
- Identify and assign a point of contact (POC) to coordinate plans with the ICLIO Grand Rounds project team.
- Have already established—or be in the early stages of implementing—an immuno-oncology (I-O) program, and be willing to discuss your I-O program practices with ACCC and ICLIO.
- Have plans to expand your immuno-oncology program over the next two years.
- Have a commitment from at least 5-10 key oncology professionals who will participate in the ICLIO Grand Rounds program.
- If the 90-minute case-based tumor board discussion format is selected, must be willing to discuss de-identified cases with ACCC and ICLIO and have commitment from 1 clinician to submit an I-O case for discussion.
- If the 60-minute ICLIO expert-led format is selected, must have commitment from 1 clinician to submit an I-O case for discussion.
- Complete this Grand Round application form.
- Provide permission for ACCC and ICLIO to publish key findings and outcomes from the ICLIO Grand Rounds on their respective websites and print publications, including but not limited to publication in white papers, social media posts, webinars, blogs, newsletters, and live education conferences.

To be considered for this opportunity, please submit this application by **May 19, 2017**, to Brissan Guardado via email ([bguardado@acc-cancer.org](mailto:bguardado@acc-cancer.org)).

**ACCC Cancer Program Name:**

---

**Name and emails of individual(s) completing this application:**

---

**What is your role on the multidisciplinary cancer care team?**

- Cancer Program Administrator
- Medical Director
- Medical oncologist
- Nurse/nurse navigator
- Pharmacist
- Cancer registry manager/coordinator
- Other: \_\_\_\_\_

**Information about your immuno-oncology program:**

1) **On average, how many patients does your program treat with immuno-oncologic agents each year (checkpoint inhibitors [anti-PD-1s, anti CTLA-4s]/vaccines/other immunotherapies used to treat patients with cancer)?**

- 0 – 25
- 26 – 50
- 51 – 75
- 76 – 100
- >100

2) **On a scale from 1 to 5, where 1 is “not at all operational” and 5 is “fully operational,” where does the immuno-oncology program fall at your institution?**

1                      2                      3                      4                      5

3) **Does your institution currently conduct scheduled Grand Rounds?**

- Yes (If yes, proceed to question 4)
- No (If no, proceed to question 6)

4) **When do your regularly scheduled Grand Rounds occur?**

- Weekly
- Monthly
- Other (please specify)

5) **Generally, how long are your Grand Rounds sessions?**

- <1 hour
- >1 hour but less than 2 hours
- >2 hours

6) **Of the immunotherapy drugs prescribed at your institution, approximately what percent are prescribed for the following tumor types? (e.g., what percent of your I-O drugs are prescribed for melanoma? Lung cancer? etc.) (Total must equal 100%.)**

Non-Small Cell Lung Cancer \_\_\_\_\_%

Melanoma \_\_\_\_\_%

Bladder Cancer \_\_\_\_\_%

Head & Neck Cancer \_\_\_\_\_%

Hodgkin Lymphoma \_\_\_\_\_%

Kidney Cancer \_\_\_\_\_%

Other \_\_\_\_\_%

7) **From a clinical-case and educational perspective, which tumor types would your institution be most interested in discussing during the ICLIO Grand Rounds program?**

- Non-Small Cell Lung Cancer
- Melanoma
- Bladder Cancer
- Head & Neck Cancer
- Hodgkin Lymphoma
- Kidney Cancer
- Other (please specify)

- 8) **Please select your preferred format for the ICLIO Grand Rounds (choose 1):**
- ICLIO expert-led presentation (e.g., educational forum) (if this option is chosen, proceed to Question 9).
  - ICLIO traditional, case-based tumor board discussion (e.g., seminar format) (if this option is chosen, proceed to Question 10).
- 9) **Please list any other immuno-oncology topics that are of potential interest to your institution:**
- 
- 10) **Which clinician will be able to provide and discuss the case for the ICLIO Grand Rounds tumor board discussion?**
- 

Thank you for your interest in participating in the  
**ICLIO Grand Rounds series.** You will be notified in  
May 2017 when a decision has been made.

ICLIO is made possible by a charitable donation from Bristol-Myers Squibb and supported by an educational grant from Merck & Co., Inc.

